Table 4 CMR findings (without controls)
Total (N = 64) | CPEO/KSS (N = 33) | MELAS/-like (N = 11) | MERRF (N = 3) | Other MM (N = 17) | p value | |
|---|---|---|---|---|---|---|
LV end-diastolic volume index ml/m2 | 67 ± 18 | 61 ± 14* | 85 ± 24 | 73 ± 15 | 66 ± 14* | 0.002 |
LV end-systolic volume index, ml/m2 | 25 ± 2 | 21 ± 8 | 37 ± 20 | 28 ± 10 | 24 ± 7 | 0.003 |
LV mass index, g/m2 | 56 ± 23 | 49 ± 11* | 90 ± 35 | 58 ± 17 | 50 ± 12* | <0.001 |
LV ejection fraction, % | 66 ± 8 | 66 ± 7 | 59 ± 12 | 62 ± 5 | 65 ± 6 | 0.09 |
LV ejection fraction <60 %, n (%) | 18 (28) | 8 (24) | 6 (55) | 1 (33) | 3 (18) | 0.26 |
LV mass/ end-diastolic volume, g/ml | 0.84 ± 0.27 | 0.84 ± 0.24 | 1.07 ± 0.31 | 0.71 ± 0.06 | 0.72 ± 0.22* | 0.008 |
LV hypertrophy in absence of AHT, n (%) | 14 (22) | 3 (9)* | 9 (82) | 1 (33) | 1 (6)* | <0.001 |
RV end-diastolic volume index ml/m2 | 66 ± 14 | 63 ± 12 | 69 ± 18 | 65 ± 9 | 72 ± 15 | 0.22 |
RV end-systolic volume index, ml/m2 | 30 ± 9 | 29 ± 9 | 30 ± 10 | 32 ± 7 | 33 ± 10 | 0.39 |
RV ejection fraction, % | 55 ± 10 | 55 ± 11 | 57 ± 8 | 51 ± 5 | 54 ± 10 | 0.75 |
LGE presence, n (%) | 21 (33) | 12 (36) | 8 (73) | 0 (0) | 1 (6)* | 0.001 |
Non-ischemic LGE presence, n (%) | 19 (30) | 10 (30)* | 8 (73) | 0 (0) | 1 (6)* | <0.001 |
Any abnormal CMR findings, n (%) | 34 (53) | 18 (55)* | 10 (91) | 1 (33) | 5 (29)* | 0.007 |